(MC) in peripheral tissues. However, its causative role in atherosclerosis is not well established and its effect on vascular inflammation has not been studied. The underlying mechanism is unknown.
ApoE deficiency, it is necessary to validate the effect of HHcy on atherogenesis in a different atherosclerosis accessible animal model free of ApoE depletion. In this study, we generated the Ldlr Ϫ/Ϫ Cbs Ϫ/ϩ mice, because both ApoE Ϫ/Ϫ and Ldlr Ϫ/Ϫ mice are widely used animal models of atherosclerosis.
Despite its established strong association with CVD, the causative role of HHcy in CVD remains controversial. Several secondary prevention trials of Hcy-lowering therapy were reported to have no benefit on combined endpoints of cardiovascular events. 10 However, Hcy lowering has been found to be beneficial in reducing cardiovascular risk in CBS-deficient patients 11 and in preventing the recurrence of stroke. [12] [13] [14] [15] [16] In the HOPE 2 Trial, Hcy lowering reduced the risk of overall stroke. 17 Such benefit was also found in a large population-based cohort study, showing that Hcy lowering due to folic acid fortification significantly reduced stroke mortality in the general population. 18 Some of the negative findings probably reflect limitations related to statistic power, relatively low levels of plasma Hcy levels prior to the treatment (plasma Hcyϭ10 -15 mol/L), comedication confounders, irreversible disease stage, and difficulty of nutritional control in selected patient populations. Therefore, it is important to develop a well-controlled animal model of Hcy-lowering therapy for severe HHcy to confirm the causative effect of HHcy and dissect the underlying mechanisms.
Recent advances in immunology have identified functional subsets of MC, which exhibit distinct pathophysiological roles. 19, 20 Mouse MC subsets can be distinguished by differential expression of an inflammatory MC marker Ly-6C. 21 Ly-6C high and Ly-6C middle MC subsets have been linked to inflammatory disease, including hypercholesterolemia and atherosclerosis, and named as inflammatory MC subsets. 19 We recently reported that severe HHcy elevated circulating Ly-6C highϩmiddle MC independent of hyperlipidemia, pointing out a new proatherogenic mechanism of HHcy. 7 However, how HHcy modulates MC subset function and its differentiation in the vessel wall has not been studied.
In this study, we created Ldlr Ϫ/Ϫ Cbs Ϫ/ϩ mice, established HHcy-inducing and Hcy-lowering strategies, and assessed the causative role of HHcy on atherogenesis, MC differentiation, and relevant inflammation systemically and in the vessel wall.
MC Differentiation Study in Primary Mouse Splenocytes and Chemical Treatment
Splenocytes were isolated from 2-month-old C57B/L6 wild-type mice, primed with low-dose recombinant interferon-␥ (rIFN␥, 100 U/mL) at plating. After 24 hours, the cells were treated with L-Hcy (500 mol/L) or L-Cys (500 mol/L), restimulated with LPS (1 g/mL) and brefeldin A (5 ng/mL), and followed with antibody (Ab) staining prior to flow cytometry analysis.
For mechanistic study, cells were treated with the folic acid (100 mol/L), 29 PEG-CAT (250U/mL) plus PEG-SOD (150U/mL), 
Non-standard Abbreviations and Acronyms

Dihydroethidium (DHE) Staining and Flow Cytometry Analysis in Primary Mouse Splenocytes
Splenocytes were harvested and incubated with DHE (2ϫ10 -6 M), a superoxide indicator, at 37°C for 30 minutes and then coincubated with monoclonal antibodies to CD11b (anti-CD11b, clone M1/ 70)-PE and Ly-6C (anti-Ly6C, AL21)-FITC (BD Pharmingen TM , San Diego, CA) for flow cytometry analysis. Superoxide anion (O 2 Ϫ )-containing cells were identified as DHE ϩ cells, 28 in both CD11b ϩ Ly6C Ϫ and CD11b ϩ Ly6C ϩ populations.
L-Hcy was freshly prepared as previously described. 30 All chemicals not specified above were purchased from Sigma-Aldrich (St. Louis, MO).
MC Cytokine Intracellular Staining
Primary mouse splenocytes were cultured and treated with L-Hcy. Cells were stained for cell surface marker Abs, fixed and permeabilized, and finally incubated with cytokine Abs, TNF-␣-PE (MP6-XT22), and IL-6-FITC (MP5-20F3).
Results
Therapeutic Diet Design
We designed a set of mouse diets containing precisely controlled synthetic nutrition ingredients, with an emphasis on controlling folate levels to the basal normal requirements. 31 As described in Table 1 , the regular rodent chow contains excessive folate and B12 (7.1 and 0.05 mg/kg diet), which are 14.2-and 5-fold greater than the basal requirement (0.5 and 5 g/kg diet) on the basis of the guidelines for adequate mouse nutrition suggested by the National Laboratory Animal Nutrition Committee. 31 This lowers the sensitivity to dietaryinduced HHcy and reduces therapeutic responsiveness in mice. Therefore, we designed a set of mouse diets containing precisely controlled synthetic nutrition ingredients, with a special emphasis on controlling folate levels to the basal requirements. Our control diet, HF (TD08028, Harlan Teklad), contains sufficient vitamins (folate 0.6 mg/kg, B12 30 g/kg, B6 8.4 mg/kg) and 21% fat. The HFϩHM diet (TD08029, Harlan Teklad) is the HF diet with up to 19.56 g/kg (2%) methionine, an amino acid precursor of Hcy, added to induce HHcy. The HFϩHMϩHV (TD08118, Harlan Teklad) is a therapeutic diet that adds B vitamins to the HFϩHM diet. It contains 6 mg/kg folate, 60 g/kg B12, 16.8 mg/kg B6, a 10-fold increase in folate content and a 2-fold increase in B6 and B12 in relation to the HFϩHM diet. We determined an average food consumption of about 3 g diet per day per mouse; B vitamin consumption in mice on HFϩHMϩHF diet was 720 g folate, 7 g B12, and 2 mg B6 per kilogram body weight per day, which are dosages used in previous human clinical trials. 32, 33 
HF؉HM Diet Induced Severe HHcy, Which Was Reversed by High Vitamin Supplementation in EGFP BM Ldlr ؊/؊ Cbs ؊/؉ Mice
The HFϩHM diet induced severe HHcy and hyperlipidemia in the EGFP BM Ldlr Ϫ/Ϫ Cbs Ϫ/ϩ mice. Plasma Hcy increased from 12.1Ϯ6.9 to 244.6Ϯ50.4 mol/L in mice fed an HFϩHM diet ( Figure 1B ), comparable to the HHcy observed in subjects in the Framingham studies (Hcy up to 219.84 mol/L). 34 The vitamin therapy effectively prevented severe HHcy and reduced plasma Hcy levels to 46Ϯ23.4 mol/L. Hyperlipedemia (441 mg/dL. TC) is similar to results seen in the ApoE Ϫ/Ϫ mice and relevant to severe hyperlipidemia in humans. 3
HHcy and Vitamin Supplementation Had No Effect on Organ Development, Plasma Lipids, Glucose, or B6/B12 Vitamin Levels, But Vitamin Supplementation Increased Plasma Folate Levels in EGFP BM Ldlr ؊/؊ Cbs ؊/؉ Mice
The HFϩHM diet did not change body weight or heart weight (data not shown), but showed a trend of increasing plasma total cholesterol (TC), triglyceride (TG), and fasting blood glucose (FBG), and reducing vitamin B12 and folate levels ( Table 2 ). Vitamin treatment with the HFϩHMϩHV diet improved plasma lipid, elevated B6 and B12 vitamins, and significantly increased plasma folate levels from 18.9Ϯ4.0 ng/mL in the HFϩHM group to 73.3Ϯ22.9 ng/mL (3.9-fold).
HHcy Increased Atherosclerosis and Accumulation of BM-Derived MCs in Atherosclerotic Lesions of Chimeric EGFP BM Ldlr ؊/؊ Cbs ؊/؉ Mice
Chimeric EGFP BM Cbs Ϫ/ϩ Ldlr Ϫ/Ϫ mice were generated by BMT from EGFP Tg mice ( Figure 1A ). The EGFP-transgenic mice express GFP in all cell types. It is well recognized that GFP is not toxic to the cells and is a useful marker to identify and follow the fate of cells transplanted to the recipient mice. 35 We traced bone marrow (BM)-derived cells by transplantation of BM cells from EGFP transgenic mice after sublethal irradiation of the recipient. The mean frequency of GFP ϩ cells in the peripheral nucleated cells was 97.9%Ϯ1.1% in chimeric EGFP BM Ldlr Ϫ/Ϫ Cbs Ϫ/ϩ mice, close to that seen in donor EGFP mice (98.2%Ϯ1.0%) ( Figure 1C ). By cross-section analysis of the aortic sinus, we Basal vitamin requirement is determined by the "Guidelines for Adequate Nutrition of Mice Suggested by National Laboratory Animal Nutrition Committee" (Endo et al 24 ) . We designed the HF diet containing sufficient vitamins and 21% fat; the HM diet added methionine up to 2%, and the therapeutic HFϩHMϩHV diet contained increased vitamins. HF, high fat; HM, high methionine; HV, high vitamin.
a Diet catalog no. of LabDiet. b Diet catalog no. of Harlan Teklad. found that severe HHcy increased atherosclerotic lesion area and its percentage in the sinus in chimeric EGFP BM Ldlr Ϫ/Ϫ Cbs Ϫ/ϩ mice fed an HFϩHM diet (18.9Ϯ6.3ϫ10 4 m 2 and 22.2%Ϯ10.7%) in comparison with that in the control mice fed an HF diet (7.7Ϯ4.9ϫ10 4 m 2 and 8.3%Ϯ4.2%) ( Figure  1D & 1E). Vitamin treatment completely prevented HHcyinduced atherosclerotic lesion, and reduced the lesion area and its percentage to that in the control mice (6.6Ϯ3.1ϫ10 4 m 2 and 8.1%Ϯ3.9%). By sequential double immunofluorescence staining with monoclonal antibodies (mAbs) anti-MOMA-2 (MC/M marker) and anti-GFP (BM origin cell marker) ( Figure 1D ), we found that BM-derived cells (GFP ϩ ) dominated the cellular population of the lesion, and largely overlapped with MC/M marker MOMA2. The vitamin treatment prevented the accumulation of GFP ϩ cells and MC/M in the lesion. By flow cytometric quantification of single-cell suspensions of the aortas, we found that HHcy increased donor BM-origin GFP ϩ population in the vessel wall from 6.7%Ϯ1.0% in mice on HF diet to 36.6%Ϯ3.2% in mice on HFϩHM diet, a 5.5-fold increase, which was reduced to 16.4%Ϯ0.9% by vitamin treatment ( Figure 1F ). Consistently, the absolute cell count of BM-origin GFP ϩ population in the aorta was increased 2.9-fold by HHcy, and completely reduced to the basal level by vitamin treatment ( Figure 1G ).
Zhang et al Hyperhomocysteinemia Causes Vascular Inflammation
HHcy Increased Total MC in the Blood, Spleen, and BM, Elevated All MC Subsets in the Spleen and BM, and Raised Ly-6C high Inflammatory MC Subset in the Blood of EGFP BM Ldlr ؊/؊ Cbs ؊/؉ Mice
Mononuclear cells (MNC) were isolated on the basis of their lower granularity and larger cell size (gate ii) ( Figure 2A ). MC was defined as CD11b ϩ MNC and further divided into 3 subsets using anti-Ly-6C Ab (Ly-6C high , Ly-6C middle , and Ly-6C low ) ( Figure 2B ). HHcy increased total MNC by 2-and 1.4-fold in the blood and spleen, respectively, and MC by 5-, 2-, and 1.6-fold in the blood, spleen, and BM, respectively ( Figure 2C ). The highest increased subsets were blood Ly-6C high and Ly-6C middle MC, the inflammatory subsets, which were increased by 4.7-and 8.8-fold in the blood, 2.6and 2.6-fold in the spleen, and 3.0-and 2.0-fold in the BM in comparison with control mice. MC Ly-6C low populations were increased by 2.5-, 1.9-, and 2.1-fold in the corresponding tissues ( Figure 2D ). Vitamin treatment prevented the increase of all MC populations in the spleen and BM, but only reversed total MC and the Ly-6C high population in the blood ( Figure 2C and 2D).
HHcy Caused Accumulation of BM-Derived and Tissue-Origin MC and M in the Aortas of EGFP BM Ldlr ؊/؊ Cbs ؊/؉ Mice
The aortic cells were first divided into donor-origin BMderived GFP ϩ and tissue-origin GFP Ϫ populations, then further, on the basis of CD11b (MC marker) and Ly-6G (myeloid granulocyte maturation marker) expression. The gate i CD11b ϩ Ly-6G ϩ cells were defined as putative M and gate ii CD11b ϩ Ly-6G Ϫ as putative MC ( Figure 3A ). HHcy increased GFP ϩ M by 9.7-fold and MC by 4.3-fold, GFP Ϫ M by 12-fold and MC 2.9-fold, and M maturation rate by 3-fold and 2.9-fold in the GFP ϩ and GFP Ϫ populations, respectively ( Figure 3B ). Vitamin treatment completely abolished the effects of HHcy on M accumulation and maturation, and significantly reduced MC levels in the aorta for both GFP ϩ and GFP Ϫ cells ( Figure 3B ).
HHcy Increased Both BM-Derived and Resident Inflammatory MC Subsets, and Promoted MC Heterogeneity in the Aorta of EGFP BM Ldlr ؊/؊ Cbs ؊/؉ Mice
Aortic retrieved cells were divided into the GFP ϩ and GFP Ϫ groups and analyzed for MC and M content using CD11b and Ly6G ( Figure 3A ). HHcy increased vessel wall GFP Ϫ M and MC by 1233% and 429%, and GFP ϩ M and MC by 970% and 294%, respectively. M maturation rate was increased by 300% for both GFP Ϫ and GFP ϩ populations. These increases were all prevented by vitamin supplementation ( Figure 3B ). MC cells (gate ii from Figure 3A ) were further divided into 4 phenotypiclly distinct populations using the Ly-6C and F4/80. The R1 cells were defined as inflammatory MC (Ly-6C highϩmiddle F4/80 Ϫ ), R2 the differentiating MC (Ly-6C highϩmiddle F4/80 ϩ ), R3 the differentiated M (Ly-6C low F4/80 ϩ ), and R4 the Ly-6C low F4/80 Ϫ MC, respectively ( Figure 3C ). HHcy increased GFP Ϫ and GFP ϩ inflammatory MC from 105Ϯ5 to 842Ϯ64 and from 44Ϯ4 to 816Ϯ2 cells per aorta, the differentiating MC from 92Ϯ44 to 784Ϯ46 and from 97Ϯ42 to 558Ϯ83, the differentiated M from 288Ϯ133 to 1095Ϯ217 and from 986Ϯ198 to 1874Ϯ350, and the Ly-6C low MC from 385Ϯ44 to 1040Ϯ3 and from 528Ϯ53 to 1624Ϯ214, respectively. Thus, HHcy Chimeric EGFP BM Ldlr Ϫ/Ϫ Cbs Ϫ/ϩ mice were generated as described in Figure 1A , fed an indicated diet at the age of 14 weeks (6 weeks after BMT) for 8 weeks, and sacrificed. Plasmas from overnight-fasted mice were collected for biochemical tests. Values represent meanϮSD. Nϭ15; P values from independent t test. Ldlr Ϫ/Ϫ indicates LDL receptor; Cbs, cystathionine ␤-synthase; HF, high fat; HM, high methionine; HV, high vitamin; TC, total cholesterol; TG, triglyceride; FBG, fasting blood glucose. *P vs HF; †P vs HFϩHM.
had similar effects on vessel wall GFP Ϫ cells as on GFP ϩ cells. The more HHcy responsive vessel wall MC populations were Ly-6C highϩmiddle F4/80 ϩ and Ly-6C highϩmiddle F4/80 Ϫ (R1 and R2) cells. The Ly-6C low F4/80 ϩ and Ly-6C low F4/80 Ϫ (R3 and R4) were less responsive to HHcy. Vitamin treatment completely prevented the induction of inflammatory and differentiating MC (R1 and R2), and Ly-6C low MC (R4) for both GFP Ϫ and GFP ϩ cells, and largely reduced the GFP Ϫ -differentiated M (R3), but had no effect on the GFP ϩ population.
HHcy Induced Systemic Inflammation in EGFP BM
Ldlr ؊/؊ Cbs ؊/؉ Mice HHcy increased plasma proinflammatory cytokines IL-6 from 52 to 76 pg/mL, TNF-␣ from 80 to118 pg/mL, and chemokine MCP-1 from 344 to 671 pg/mL, respectively ( Figure 4A ). Vitamin treatment prevented the induction of MCP-1, TNF-␣, and IL-6. Furthermore, plasma IL-6, TNF-␣, and MCP-1 levels positively correlated with Hcy levels ( Figure 4B ).
L-Hcy Promoted Inflammatory MC Differentiation and Proinflammatory Cytokine Production in Primary Mouse Splenocytes
L-Hcy (100, 200, and 500 mol/L) increased inflammatory CD11b ϩ Ly-6C high MC population by 143%, 149%, and 173%, and CD11b ϩ Ly-6C middle MC by 130%, 154%, and 150%, in a dose-dependent manner in rIFN␥-primed primary mouse splenocytes ( Figure 5B and 5C ). However, L-Cysteine, a sulfhydryl-containing amino acid control, showed a trend in increasing CD11b ϩ Ly-6C high MC, but did not change CD11b ϩ Ly-6C middle MC population ( Figure  6B and 6C ). L-Hcy increased TNF-␣-producing CD11b ϩ Ly-6C middleϩhigh inflammatory MC (Q2) from 65Ϯ15 to 228Ϯ46 per million cells (3.5-fold increase), IL-6-producing Q2 cells from 66Ϯ19 to 159Ϯ32 (2.4fold), and dual cytokine-producing Q2 cells from 740Ϯ208 to 2121Ϯ430 (2.9-fold), but had no effect on single cytokine-producing Q1 population, CD11b ϩ Ly-6C low residential MC, and reduced dual cytokine-producing Q1 cells ( Figure 6D and 6E) . 
Folic Acid and Antioxidant Reagents Prevented L-Hcy-Induced Inflammatory MC Differentiation in Primary Mouse Splenocytes
L-Hcy (500 mol/L) increased Ly-6C high and Ly-6C middle subsets by 191% and 147%, respectively. Folic acid (100 mol/L) did not change the populations of Ly-6C high and Ly-6C middle subsets (101% and 94%), but prevented the increase of Ly-6C high and Ly-6C middle subsets induced by HHcy (from 191% and 147% to 80% and 104%, respectively). The combination of SOD (150 U/mL) and catalase (250 U/mL), a superoxide anion scavenger and a hydrogen peroxide metabolizing enzyme, respectively, reduced basal Ly-6C high to 72% and had no effect on Ly-6C middle subsets (100% of the control group). The combination of SOD and catalase prevented Hcy-induced Ly-6C high (93% of the con-trol) and Ly-6C middle (99% of the control) subsets. Apocynin (100 mol/L), an antioxidant, 36 reduced the Hcy-induced Ly-6C high subset to 105% and Ly-6C middle subset to 114%; FA and antioxidants did not change Ly-6C low subset in the presence or absence of Hcy (Figure 5A , 5B, and 5C).
Folic Acid and Antioxidant Reagents Reduced L-Hcy-Induced Superoxide Anion Production in Inflammatory MC
L-Hcy (500 mol/L) increased superoxide anion producing cells (the DHE ϩ cells) by 167% (from 10.2%-17%) in CD11b ϩ /Ly-6C ϩ inflammatory MC (Figure 7A, 7B, and 7C ). Hcy-induced DHE ϩ CD11b ϩ /Ly-6C ϩ inflammatory MC was completely reversed to 100%, 102%, and 98% if pretreated with FA (100 mol/L), apocynin (100 mol/L), or SOD plus Catalase. The CD11b ϩ /Ly-6C Ϫ residential MC had very low detectable superoxide anion (2%). DL-Hcy (500 mol/L) did not increase superoxide production in CD11b ϩ /Ly-6C Ϫ residential MC. FA and antioxidants did not significantly change the population of DHE ϩ CD11b ϩ /Ly-6C Ϫ MC.
Discussion
In this study, we examined the causative role and mechanism of HHcy in atherogenesis and MC differentiation by using a sophisticated experimental model system consisting of a novel Ldlr Ϫ/Ϫ Cbs Ϫ/ϩ mouse line and a set of relevant diets for HHcy inducing and Hcy lowering. We used a group of state-of-the-art technologies including GFP traced BM transplantation, FACS analysis of MC subsets in the vessel wall, intracellular cytokine staining, and in vitro MC differentiation in mouse primary splenocytes. We report 5 major findings here: (1) severe HHcy accelerates atherosclerosis independent of apoE deficiency, (2) severe HHcy promotes MC differentiation of both BM and tissue origin in peripheral tissues and in the vessel wall, (3) Hcy-lowering therapy via elevation of plasma folate levels prevents HHcy-induced atherosclerosis and inflammatory MC differentiation, (4) HHcy induces inflammatory MC differentiation leading to proinflammatory cytokine production and systemic inflammation, and (5) Hcy promotes inflammatory MC subset differentiation via oxidative stress in primary splenocytes.
The CBS-deficient mouse was established by Dr. Nobuyo Maeda and colleagues. 22 Plasma Hcy levels are doubled in Cbs Ϫ/ϩ mice (Hcy 6 -14 mol/L), in comparison with Cbs ϩ/ϩ mice (Hcy 3-8 mol/L) on a regular rodent chow. 22, 4 However, if challenged with a high-vitamin-containing HM diet, Cbs Ϫ/ϩ mice developed severe HHcy (plasma Hcy 140 mol/L), and the Cbs ϩ/ϩ mice had moderate HHcy (plasma Hcy 40 mol/L). 4 In this study, we designed an HFϩHM diet containing low but sufficient vitamins, which induced aggressive severe HHcy (plasma Hcy 244 mol/L) in the Ldlr Ϫ/Ϫ Cbs Ϫ/ϩ mice. These data suggest that CBS activity is largely reduced in Cbs Ϫ/ϩ mice, which cannot catabolize excessive substrate (methionine) provided by HM diet.
The Ldlr Ϫ/Ϫ Cbs Ϫ/ϩ mouse is a valid disease model for HHcy-induced pathology, in which atherosclerosis can be examined independent of ApoE deficiency. In addition, we lowered folate/B vitamin content to basic nutritional requirement levels (Table 1) in the HF and HFϩHM diets. This strategy not only ensures adequate nutrition of mice 31 and eradicates metabolic disturbances that may be caused by the folate-free diet previously used by the others to induce HHcy, 37 but also increases the sensitivity to Hcy-lowering interventions. Plasma Hcy is increased to 244 mol/L in mice fed an HFϩHM diet; this is reduced to 46 mol/L utilizing folate-emphasized vitamin combination therapy at clinically tested dosages ( Figure 1A) . 32, 33 Our data provide strong evidence supporting the causative role of HHcy in atherogenesis because Hcy-lowering therapy completely prevented HHcy-induced atherosclerotic lesion (Figures 1, 2, and 4) . This is consistent with Hcy-lowering studies in CBS-deficient humans in which lower plasma Hcy significantly reduced cardiovascular events. 11 Our preventive strategy by supplement therapeutic vitamins (HV) in the HHcy diet (HM) clearly demonstrated the benefit of preventive Hcy-lowering therapy. Studies are underway to determine whether Hcy lowering can reverse CV outcomes in disease models in light of the clinical therapy condition.
Vitamin treatment increased serum folate level by 3.9-fold, but did not significantly change B6/B12 vitamin levels ( Table  2 ). These data suggest that folate modulation is sufficient to prevent the induction of atherosclerotic lesion formation and inflammatory MC differentiation in HHcy, whereas B6/B12 supplement may not be critical for the regression of atherosclerosis and MC differentiation. Figure 1A . Plasma IL-6, TNF-␣, and MCP-1 levels were assessed by ELISA. B, Correlation analyses were performed between plasma cytokines and Hcy levels. One data dot represents data from a single mouse; nϭ9, *PϽ0.05 versus HFϩHM diet. Values represent meanϮSEM, probability values from independent t test (A) and Spearman correlation analysis (B). HHcy indicates hyperhomocysteinemia; HF, high fat; HM, high methionine; HV, high vitamin; MC, monocytes; M, macrophage; MCP-1, monocyte chemoattractant protein-1.
Vitamin therapy reduced the HHcy-induced expansion of all 3 MC subsets to basal levels in the spleen and BM, and CD11b ϩ Ly-6C high population, but not CD11b ϩ Ly-6C mid/low MC in the blood. These data suggest that HHcy stimulates all MC subset replenishment in the spleen and BM, and selectively promotes the release of CD11b ϩ Ly-6C high MC to the blood (Figure 2) . Because blood CD11b ϩ Ly-6C high MC levels respond to the treatment and correspond to atherosclerotic lesion size, it is a valid therapeutic readout for cardiovascular intervention.
We found that HHcy-accelerated atherosclerotic lesion composes predominately BM-derived MC/M and is enhanced by inflammatory MC in Ldlr Ϫ/Ϫ Cbs Ϫ/ϩ mice (Figures 1 and 3) . This is consistent with our previous observation in Tg-hCBS Cbs Ϫ/Ϫ mice, 7 extending the theory that MC accumulation in HHcy increases proportionately with lesion size. 38 The accumulation of blood origin GFP ϩ MC/ M in the lesion is likely related to Hcy-induced endothelial activation and MC transmigration, which are under active investigation in our laboratory.
Under steady state conditions, CD11b ϩ Ly-6C high BM MC are released into the peripheral blood and are thought to become CD11b ϩ Ly-6C middle MC before they form CD11b ϩ Ly-6C low MC. 19, 20, 39 By flow cytometry analysis of whole aortic cell suspensions, we found that HHcy increases the aortic accumulation of all subsets of MC and M of both GFP ϩ and GFP Ϫ cells (Figure 3) . Importantly, the most dramatic increased populations are Ly-6C highϩmiddle MC (8and 8.5-fold increases for GFP Ϫ F4/80 ϩ and F4/80 Ϫ , and 18.5-and 5.8-fold for GFP ϩ F4/80 ϩ and F4/80 Ϫ cells, respectively) and CD11b ϩ Ly-6G ϩ M (12-and 9-fold for GFP Ϫ and GFP ϩ cells, respectively). These data indicate that Ly-6C highϩmiddle MC is the most responsive MC to be recruited (GFP ϩ ) into and expanded (both GFP Ϫ and GFP ϩ ) in the vessel wall, which are further differentiated into M and contribute to vessel wall inflammation and atherosclerosis. Vitamin treatment completely reversed inflammatory and differentiating MC induction, for both GFP Ϫ and GFP ϩ cells, reduced GFP Ϫ differentiated M, but had no effect on GFP ϩ -differentiated M, which is Ly-6C low F4/80 ϩ and has less inflammatory potential. It is likely that BM-origin inflammatory MC and M are more responsive to vitamin therapy, but the BM-origin differentiated M, which has less inflammatory potential is not responsive. These data provide strong evidence supporting the causative role of HHcy in promoting recruitment and differentiation of inflammatory MC and M and maturation of both BM-and tissue-origin cells in the vessel wall. Our studies support the notion that Hcy-lowering therapy reverses MC differentiation and tissueorigin M differentiation, but not BM-origin M differentiation in the vessel wall.
We and others have suggested that HHcy induces systemic inflammation 7,37 and cytokine production. 40 Here, we demonstrate that HHcy increases plasma proinflammatory cyto-kine (IL-6 and TNF␣), which can be produced by MC, and chemokine (MCP-1) levels, which were prevented by vitamin treatment (Figure 4 ). Furthermore, we show that L-Hcy (100 -500 mol/L) induces the differentiation of inflammatory MC subsets ( Figure 5 ), which are responsible for Hcy-induced TNF-␣ and IL-6 production in a MC differentiation model in primary mouse splenocytes ( Figure 6 ). These data provide strong evidence supporting a causative role for HHcy in inducing systemic inflammation by promoting Ly-6C highϩmiddle MC differentiation. Figure 6 . L-Hcy promoted rIFN␥-induced inflammatory MC formation and proinflammatory cytokines production in primary mouse splenocytes. A, MC differentiation study. Splenocytes from WT mice were primed with rIFN␥ at plating and treated with L-Hcy for 48 hours. Cells were stained with CD11b and Ly-6C mAbs and analyzed by flow cytometry. Gate ii cells are MNC. B and C, Representative dot plots and quantification of MC subsets. Gate ii MNC were selected. MC were defined as CD11b ϩ MNC and divided into Ly-6C high , Ly-6C middle , and Ly-6C low subsets. D and E, Representative dot plots and quantification of intracellular inflammatory cytokine analysis. Hcy-treated mouse splenocytes were stained for surface markers with anti-CD11b (MC marker) and anti-Ly-6C (inflammatory MC marker) mAbs, and followed with intracellular cytokine staining by incubating with anti-TNF-␣ and anti-IL-6, or isotype-matched mAbs after permeablization. MC was divided into 2 subsets: CD11b ϩ Ly-6C low MC (Q1) and inflammatory MC CD11b ϩ Ly-6C highϩmiddle (Q2), and further each was divided into 3 groups (R1, R2, and R3) on the basis of intracellular cytokine production. Values were normalized with that from isotype stain. Values represent meanϮSEM, nϭ9, probability values from independent t test,*PϽ0.05 versus rIFN␥ control. Hcy indicates homocysteine; Cys, cysteine; MNC, mononuclear cells; MC, monocytes; Low, Ly-6C low subset; Mid, Ly-6C middle subset; High, Ly-6C high subset.
Finally, we demonstrate that HHcy-induced inflammatory MC differentiation and superoxide anion production can be inhibited by folic acid, antioxidant SODϩcatalase, or apocynin ( Figures 5 and 7) . These data suggest that HHcy-induced inflammatory MC differentiation is mediated, in large part, through oxidative stress. Future studies should be important in identifying mechanisms underlying Hcy-induced superoxide anion production in MC.
In summary, we provide direct evidence supporting a new theory that the proinflammatory effects of HHcy modulate MC recruitment and differentiation, thereby contributing to atherogenesis. HHcy enriches MC in the spleen and BM, and selectively promotes the release of CD11b ϩ Ly-6C high MC to the blood, which contributes to systemic inflammation and vessel wall MC accumulation. HHcy facilitates inflammatory Ly-6C highϩmiddle MC recruitment and differentiation, and M differentiation/ maturation of both BM-and tissue-origin in the vessel wall, thereby accelerating atherogenesis. The observation that vitamin therapy largely decreases plasma Hcy levels in parallel with declines in inflammatory markers, circulating and aortic inflammatory MC differentiation, and atherosclerotic lesion formation, establishes the idea that HHcy is a cause, not merely a bystander or marker for systemic inflammation and atherosclerosis, at least in mice. Our data also indicate that managing plasma folate levels is associated with Hcy lowering and complete protection against atherosclerosis and inflammatory MC differentiation.
Conclusion
These results suggest that HHcy promotes atherosclerosis by facilitating inflammatory MC differentiation via oxidant stress.
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